Dr. Steven Theriault reports

CYTOPHAGE ENTERS EUROPEAN POULTRY MARKET WITH START OF AVIPHAGE PILOT STUDY

Taking steps to enter the European poultry market, Cytophage Technologies Ltd. is pursuing the data required for approval of its flagship AviPhage product through a European-based broiler chicken pilot study.

The successful completion of this trial will provide data to support an application for European Medicines Agency (EMA) product approval.

AviPhage is a bacteriophage-based poultry solution that has been shown to promote gut health, increase bird weight, improve feed conversion ratio, decrease signs of disease and reduce mortality.

Highlights:

• The trial will be conducted on broiler chickens for 35 days, with trial data expected to be available within 60 days. The trial will measure key performance indicators that prove product efficacy such as mortality, feed conversion rate, weight gain and signs of disease.
• A successful trial will demonstrate that the study group that was given AviPhage performs better than the control group that did not receive AviPhage, particularly with respect to increased weight, improved feed conversion ratio and decreased mortality.
• Subsequently, Cytophage plans to conduct a larger study in a European commercial barn to further demonstrate the utility and efficacy of AviPhage in real-world conditions.
• The data accumulated from these studies will support Cytophage's objectives to enter into the European Union (EU) market.
• All EU member countries have banned the use of antibiotics for disease prevention and as growth promoters, and poultry producers are evaluating antibiotic alternatives that will manage bacteria in poultry.

Cytophage plans to use these trial data for its regulatory submission for product approval to the EMA. The EU is one of the largest poultry producers globally with a total production of over six billion broiler chickens each year, representing a highly desirable market with substantial commercial potential for Cytophage.

Cytophage chief executive officer Dr. Steven Theriault commented: "We continue to strategically collect data required for our product approval in the EU. We have every confidence that AviPhage will prove to be a product that farmers will want to use in their barns to improve and maintain the health of their flocks. Fewer mortalities and healthier birds positively impact the bottom line for poultry producers."

The company also wishes to announce that it has filed its financial results for the year ended Dec. 31, 2024. The audited consolidated financial statements should be read in conjunction with the accompanying management discussion and analysis for the year ended Dec. 31, 2024. All documents are available on SEDAR+ on the company's profile page.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular-level or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health, which offers a fast track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO (World Health Organization) predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production, including 27 EU countries, the United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.